Is pharmaceutical R&D just a game of chance or can strategy make a difference?

Drug Discovery Today

Volumn 9, Issue 1, 2004, Pages 18-26

  Schmid, Esther F ^a   Smith, Dennis A ^a  

^a PGRD   (United Kingdom)

Author keywords

Drug Discovery; Innovation; Pharmaceutical R D; Pharmaceutical Science; Strategy

Indexed keywords

CYTOTOXIC AGENT; PHOSPHOTRANSFERASE INHIBITOR;

COMPETITION; COMPUTER MODEL; CYTOTOXICITY; DRUG INDUSTRY; DRUG MECHANISM; DRUG TARGETING; ECONOMIC ASPECT; FEASIBILITY STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ONCOLOGY; ORGANIZATION; REVIEW;

ANTI-HIV AGENTS; BIOTECHNOLOGY; DRUG APPROVAL; DRUG INDUSTRY; HIV INFECTIONS; PHARMACOLOGY;

EID: 0842349388     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)02951-4     Document Type: Review

References (14)

1. Drews J. Strategic trends in the drug industry. Drug Discov. Today. 8:2003;411-420.
2. Capdeville R., et al. Gleevec (STI571, Imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1:(7):2002;493-502.
3. AstraZeneca (2003) AstraZeneca receives FDA approval for new cancer drug Iressa (gefitinib). ( http://www.iressa-us.com ).
4. Schumpeter J.A. The Theory of Economic Development. 1934;Harvard University Press.
5. Grant R.M. Contemporary Strategy Analysis. 4th edn:2002;Blackwell.
6. Schmid E.F., Smith D.A. Discovery, innovation and the cyclical nature of the business - a bright future for the pharmaceutical industry. Drug Discov. Today. 7:2002;563-568.
7. Gilmartin, R.V. (2002) Closing remarks at annual business briefing: 'We see no shortage of opportunities for new medicines. The flow of new discoveries industry-wide tends to be somewhat cyclical.' http://www.merck.com/newsroom/ executive_speeches/121002a.html.
8. Frank R.G. New estimates of drug development costs. J. Health Econ. 22:2003;325-330.
9. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility ad permeability in drug discovery. Adv. Drug Deliv. Rev. 23:1997;3-25.
10. Smith D.A., et al. Pharmacokinetics and metabolism in drug design. Methods and Principles in Medicinal Chemistry. 13:2001;99-121.
11. Beresford A.P., et al. The emerging importance of predictive ADME simulation in drug discovery. Drug Discov. Today. 7:2002;109-116.
12. Reynolds, T. (2003) The search for reasons behind drug approval slump. Dialogos news ( http://www.preclinica.com ).
13. Achilladelis B. (1999) Innovation in the Pharmaceutical Industry. In Pharmaceutical Innovation: Revolutionizing Human Health, (Landau, R. et al., eds), p.18-20, Chemical Heritage Foundation, Philadelphia, USA.
14. Earl, M.J. and Hopwood, A.G. [1981] From Management Information to Information Management, In The Information Systems Environment North-Holland, Henry C. Lucas et al., Amsterdam.